Race/ethnicity, social class, and prevalence of breast cancer prognostic biomarkers: A study of white, black, and Asian women in the San Francisco Bay area

Ethnicity and Disease

Volumn 7, Issue 2, 1997, Pages 137-149

  Krieger, Nancy ^a   Van Den Eeden, Stephen K ^b   Zava, David ^c   Okamoto, Akiko ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DIVISION OF RESEARCH   (United States)

^c Aeron Biotechnology Inc

Author keywords

Asian; Black; Breast Cancer; Prognostic Biomarkers; Race ethnicity; Social Class; Socioeconomic Factors

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; ASIAN; ASIAN AMERICAN; BLOOD; BREAST TUMOR; CAUCASIAN; CONFIDENCE INTERVAL; ETHNOLOGY; FEMALE; HUMAN; MORTALITY; NEGRO; PROGNOSIS; RISK; SOCIAL CLASS; SOCIOECONOMICS; SURVIVAL;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN AMERICANS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CONFIDENCE INTERVALS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; ODDS RATIO; PROGNOSIS; SOCIAL CLASS; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS;

EID: 0031086861     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Miller BA, Ries LAG, Hankey BG, Kosary CL, Edwards BK, eds. Cancer Statistics Review: 1973-1989. Bethesda, Md: National Cancer Institute; 1992. NIH Pub. No. 92-2789.
2. Cancer Among Blacks and Other Minorities: Statistical Profiles. Bethesda, Md: National Cancer Institute, Division of Cancer Prevention and Control; 1986. NIH Pub. No. 86-2785.
3. LeMarchand L. Ethnic variation in breast cancer survival: a review. Breast Cancer Res Treat. 1991; 18:S119-S126.
4. Eley JW, Hill HA, Chen VS, Austin DR Wesley MN, Muss HB, et al. Racial differences in survival from breast cancer: Results of the National Cancer Incidence Black/White Cancer Survival Study. JAMA. 1994;272:947-954.
5. Roach M III, Alexander M. The prognostic significance of race and survival from breast cancer: A model for assessing the reliability of reported survival differences. J Natl Med Assoc. 1995;85: 214-224.
6. Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995;55:1485-1490.
7. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among White, Hispanic, and Black women in the United States. J Natl Cancer Inst. 1994;86:705-712.
8. Simon MS, Severson RK. Racial differences in survival of female breast cancer in the Detroit metropolitan area. Cancer. 1996;77:308-314.
9. Sugarman JR, Dennis LK, White E. Cancer survival among American Indians in Western Washington State (United States). Cancer Causes Control. 1994;5:440-448.
10. Delgado DJ, Lin WY, Coffey M. The role of Hispanic race/ethnicity and poverty in breast cancer survival. Puerto Rico Health Sci J. 1995;14:103-116.
11. Ansell D, Whitman S, Lipton R, Cooper R. Race, income and survival from breast cancer at two public hospitals. Cancer. 1993;72:2974-2978.
12. Wells BC, Horm JW. Stage at diagnosis in breast cancer: Race and socioeconomic factors. Am J Public Health. 1992;82:1383-1385.
13. Gordon NH, Crowe JP, Brumberg DJ, Berger NA. Socioeconomic factors and race in breast cancer recurrence and survival. Am J Epidemiol. 1992; 135:609-618.
14. Bassett MT, Krieger N. Social class and black-white differences in breast cancer survival. Am J Public Health. 1986;76:1400-1403.
15. Dayal H, Power RN, Chiu C. Race and socioeconomic status in survival for breast cancer. J Chronic Dis. 1982;35:675-683.
16. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relationship between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329:325-331.
17. Berg J, Ross R, Latourette HB. Economic status and survival of breast cancer patients. Cancer. 1977;39:467-477.
18. Morrison A, Loew CR, MacMahon B, Warram J, Yuasa S. Survival of breast cancer patients related to incidence risk factors. Int J Cancer. 1972; 9: 470-476.
19. Shea M. Dynamics of Economic Well-Being: Poverty, 1991 to 1993, Current Population Reports. Washington, DC: US Government Printing Office: US Bureau of the Census, 1995. Series P70-45.
20. Eller TJ. Household Wealth and Asset Ownership: 1991. Current Population Reports. Washington, DC: US Government Printing Office: US Bureau of the Census, 1994; Series P70-34.
21. Ragland KE, Selvin S, Merril DW. Black-white differences in stage-specific survival: analyses of seven selected sites. Am J Epidemiol. 1991;133: 672-682.
22. Jones BA, Kasl SV, Curnen MGM, Owens PH, Dubrow R. Can mammography screening explain the race difference in stage at diagnosis of breast cancer? Cancer. 1995;75:2103-2113.
23. Weiss SE, Tartter PI, Ahmed S, Brower ST, Brusco C, Bossolt K, Amberson JB, Bratton J. Ethnic differences in risk and prognostic factors for breast cancer. Cancer. 1995;76:268-274.
24. Gordon N. Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol. 1995;142:796-803.
25. Chen VW, Correa P, Kurman RJ, Wu X-C, Eley JW, Austin D, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers & Prev. 1994;3:127-135.
26. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst. 1993;85:1206-1219.
27. Klijn JG, Berns EM, Bontenbal M, Foekens J. Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev. 1993; Suppl B:45-63.
28. Merkel DE. Prognostic markers in early breast cancer. Contemporary. Oncology. 1992;September:53-60.
29. Koenders PG, Beex LV, Kienhuis CB, Klooppenborg PW, Benraad TJ. Epidermal growth factor receptor and prognosis in human breast cancer: A prospective study. Breast Cancer Res Treat. 1993; 25:21-27.
30. Klijn JG, Berns PM, Schmilz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev. 1992;13:3-17.
31. Winstanley JH, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM, Rudland PS. Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer. 1993;67:767-772.
32. Ravdin PM. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat. 1993;24:219-226.
33. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, et al. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J. Clin Oncol. 1993;11:36-43.
34. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ, et al. Correlation of HER-2/new amplification with expression and with other prognostic factors in 1103 breast cancer cases. J Natl Cancer Inst. 1992;84:1279-1282.
35. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up. J Clin Oncol. 1992;10:1044-1048.
36. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP et al. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res. 1991;51:624-628.
37. Rio MC, Bellocq JP, Gairard B, Rasmessen UB, Krust A, Koehl C, et al. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA. 1987;84:9243-9247.
38. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1993; 85:965-970.
39. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst. 1992;84:1109-1114.
40. Isola JJ, Helin JH, Helle MJ, Kallioniemi OP. Evaluation of cell proliferation in breast carcinoma: Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990;65:1180-1184.
41. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991;67:421-428.
42. Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathology. 1992;168:357-363.
43. Lesser ML, Rosen PP, Senie RT, Duthie K, Menendez-Botet C, Schwartz MK. Estrogen and progesterone receptors in breast carcinoma: correlations with epidemiology and pathology. Cancer. 1981;48:299-309.
44. Schwartz MR, Randolph RL, Panko WB. Carcinoembryonic antigen and steroid receptors in the cytosol of carcinoma of the breast. Relationship to pathologic and clinical features. Cancer. 1985;55: 2464-2471.
45. Stanford JL, Szklo M, Boring CC, Brinton LA, Diamond EA, Greenberg RS, et al. A case-control study of breast cancer stratified by estrogen receptor status. Am J Epidemiol. 1987;125:184-194.
46. Hulka BS, Chambless LE, Wilkinson WE, Deubner DC, McCarty KS Sr, McCarty KS Jr. Hormonal and personal effects on estrogen receptors in breast cancer. Am J Epidemiol. 1984;119:692-704.
47. Natarajan N, Nemoto T, Mettlin C, Murphy GR Race-related differences in breast cancer patients. Results of the 1982 national survey of breast cancer by the American College of Surgeons. Cancer. 1985;56:1704-1709.
48. Beverly LN, Flanders WD, Go RC, Soong SJ. A comparison of estrogen and progesterone receptors in black and white breast cancer patients. Am J Public Health. 1987;77:351-353.
49. Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. Cancer. 1996;77:1465-1471.
50. Ownby HE, Frederick J, Russo J, Brooks SC, Swanson GM, Heppner GH, et al. Racial differences in breast cancer patients. JNCI. 1985;75:55-60.
51. Krieger N, Wolff MS, Hiatt RA, Rivera M, Vogelman J, Orentreich N. Breast cancer and serum organochlorines: a prospective study among white, black, and Asian women. JNCI. 1994;86:589-599.
52. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703-710.
53. Krieger N. Women and social class: A methodological study comparing individual, household, and census-based measures as predictors of black/white differences in reproductive history. J Epidemiol Commun Health. 1991;45:35-42.
54. Kleinbaum DG, Kupper LI, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. London, England: Lifetime Learning Pub; 1982.
55. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol. I. The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980.
56. SAS Institute, Inc. SAS Language and Procedures: Usage, Version 6.0. Cary, NC: SAS Institute, Inc; 1990.
57. Geronimus AT, Bound J, Neidert LJ. On the validity of using census geocode data to proxy individual socioeconomic characteristics. J Am Stat Assoc. 1996;91:529-537.
58. Wilbur DC, Willis J, Mooney RA, Fallon MA, Moynes R, di Sant'Agenese P. Estrogen and progesterone receptor detection in archival formaline-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the dextran-coated charcoal assay. Modern Pathol. 1992;5:79-84.
59. Pertschuk LP, Geldman JG, Kim Y-D, Braithwaite L, Schneider F, Braverman AS, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H22SPγ in frozen sections or cytosol-based ligand-binding assay. Cancer. 1996;77:2514-2519.
60. Centers for Disease Control. Use of race and ethnicity in public health surveillance. Summary of the CDC/ATSDR workshop. Atlanta, Georgia, March 1-2, 1993. MMWR. 1993;42(RR-10):1-16.
61. Hahn RA, Stroup DF. Race and ethnicity in public health surveillance: Criteria for the scientific use of social categories. Public Health Rep. 1994;109: 7-15.
62. Williams DR, Collins C. US socioeconomic and racial differences in health: patterns and explanations. Annu Rev Social 1995;21:349-386.
63. Krieger N, Rowley DL, Herman AA, Avery B, Phillips MT. Racism, sexism, and social class: implications for studies of health, disease, and wellbeing. Am J Prev Med. 1993;9(suppl 2):82-122.
64. Garrett PA, Hulka BA, Kim YL, Farber RA. HRAS protooncogene polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 1993; 2:131-138.
65. Carnon AG, Ssemwogerere A, Lamont DW, Hole DJ, Mallon EA, George WD, et al. Relation between socioeconomic deprivation and pathological prognostic factors in women with breast cancer. Br Med J. 1994;309:1054-1057.
66. Krieger N. Exposure, susceptibility, and breast cancer risk: a hypothesis regarding exogenous carcinogens, breast tissue development, and social gradient, including black/white differences, in breast cancer incidence. Breast Cancer Res Treat. 1989;13:205-223.